Naturally occurring and man-made (synthetic) fibers of respirable sizes are substances that have been identified by the U.S. Environmental Protection Agency (U.S. EPA) as priority substances for risk reduction and pollution prevention under the Toxic Substances Control Act (TSCA). The health concern for respirable fibers is based on the link of occupational asbestos exposure and environmental erionite fiber exposure to the development of chronic respiratory diseases, including interstitial lung fibrosis, lung cancer, and mesothelioma in humans. There is also considerable laboratory evidence indicating that a variety of fibers of varying physical and chemical characteristics can elicit fibrogenic and carcinogenic effects in animals under certain exposure conditions. This paper discusses key scientific issues and major default assumptions and uncertainties pertaining to the risk assessment of inhaled fibers. This is followed by a description of the types of assessment performed by the U.S. EPA to support risk management actions of new fibers and existing fibers under TSCA. The scope and depth of these risk assessments, however, vary greatly depending on whether the substance under review is an existing or a new fiber, the purpose of the assessment, the availability of data, time, and resources, and the intended nature of regulatory action. In general, these risk assessments are of considerable uncertainty because health hazard and human exposure information is often incomplete for most fibers. Furthermore, how fibers cause diseases and what specific determinants are critical to fiber-induced toxicity and carcinogenicity are still not completely understood. Further research to improve our knowledge base in fiber toxicology and additional toxicity and exposure data gathering are needed to more accurately characterize the health risks of inhaled fibers.
Introduction
A major goal of the U.S. Environmental Protection Agency (U.S. EPA) is the prevention, reduction, or elimination of harmful pollutant releases into the general environment. Naturally occurring and man-made (synthetic) fibers of respirable sizes are substances that have been identified as priority substances for risk reduction and pollution prevention. The health concern for respirable fibers is based on the link of occupational asbestos exposure and environmental erionite fiber exposure to the development of chronic respiratory diseases, including interstitial lung fibrosis, lung cancer, and mesothelioma in humans (1) This article describes the risk assessment approaches utilized by the U.S. EPA/OPPT in characterizing human health risks of exposure to new and existing fibers i.e., fibers that are listed on the TSCA inventory other than asbestos. This paper begins with a brief overview of the general principles of human health risk assessment and a discussion of the major scientific issues, uncertainties, and default assumptions pertaining to the risk assessment of inhaled fibers, and of research needs to improve the scientific basis for future risk assessments. This is followed by a description of the types of assessment performed by the U.S. EPA/OPPT to support risk management actions of new fibers and existing fibers under TSCA. Attention is focused on the kinds of scientific information and key factors that are considered in the hazard and dose-response assessments of the risk assessment process. Exposure assessment is only briefly addressed. The risk assessment of asbestos conducted by the U.S. EPA will not be discussed here, as it can be found elsewhere (4).
General Principles of Risk Assessment
Risk assessment involves the analysis and synthesis of the entire knowledge base on an environmental agent to characterize the anticipated risk from human exposure to the agent. The U.S. EPA has followed the basic National Research Council risk assessment paradigm (5,6) as a foundation for its human health risk assessment guidance (7) (8) (9) (8) . It is recognized that such extrapolation does not necessarily give a realistic prediction of the risk but is consistent with the agency's goal to provide an estimate of the upper limit to risk.
In contrast, based on our understanding of homeostatic and adaptive mechanisms, the default approach for dose-response assessment of noncancer toxicity, i.e., toxicity other than cancer and gene mutations, assumes an identifiable threshold below which effects are not observable (10, 11) . It should be noted, however, that future case-specific knowledge of the mechanisms of chemically induced toxicity and carcinogenicity may blur this distinction between approaches for noncancer toxicity and carcinogenicity.
The exposure assessment identifies the likely sources of human exposures to the environmental agent, environmental pathways for exposure (e.g., air, water, soil, food), potential routes of exposure (e.g., oral, dermal, inhalation), populations at risk, including those of highly exposed groups and highly susceptible groups, and estimates exposure and dose levels that impact the exposed individuals or populations. The exposure assessment relies on many kinds of information, some based on actual measurements and some developed using predictive models and surrogate data.
Risk characterization, the last step in risk assessment, is the integrated analysis of the preceding three steps in risk assessment to reach a conclusion about the nature and magnitude of expected risk. The predicted risk can be qualitative (e.g., high or low probability) or quantitative (e.g., one in a million probability of occurrence (12) .
The role of fiber-induced fibrosis in carcinogenesis is not clear. Macrophage lysis and chronic inflammation induced by fiber exposure may not only lead to lung fibrosis but also to the development of some lung tumors in rats. Other rat lung tumors, however, appear to have no relationship to fibrotic scar.
Critical Determinants ofFiber
Toxicity and Cacinogenicity Current scientific knowledge indicates that a major determinant of fiber toxicity and carcinogenicity is fiber dimension. There is extensive evidence relating to the importance of fiber size in lung deposition and clearance of fibers, which in turn govern the bioavailability of fibers at target tissues (13) . Fiber diameter is the major determinant for the deposition of fibers. Only fibers less than about 3.5 pm in diameter can reach the alveolar spaces. Fiber length also influences the deposition and clearance of fibers. Fibers longer than 20 pm are more readily deposited by interception at airway bifurcations. In general, short fibers (< 5 pm) are cleared more rapidly than long fibers (> 5 pm). Fiber size also plays an important role in relation to cellular mechanisms of toxicity and carcinogenicity. Long fibers of a given fiber type are generally more biologically active than shorter fibers, regardless of the measured biological end points such as cytoxicity, cell transformation, or aneuploidy. Furthermore, long fibers (> 5 pm) are more carcinogenic and fibrogenic than short fibers of asbestos and other fibers (< 5 pum) in chronic studies in rats by inhalation (14, 15) or intracavitary injection (2, 3) .
Fiber biopersistence may also be an important determinant of fiber toxicity and carcinogenicity. The concept of biopersistence arose from the observation that different natural and synthetic fibers have different lung retention characteristics; some persisting over long periods, others being less persistent. It has been hypothesized that a fiber with critical dimensions will be carcinogenic if it is sufficiently durable to remain chemically and physically intact in lung tissue in close contact with the target cells (3) . Although more durable fibers appear to be more carcinogenic than more soluble fibers e.g., refractory ceramic fiber (RCF) versus glass fiber, neither the influence of biopersistence on fibrogenesis and carcinogenesis nor the length of time required for a fiber to remain in the lung to exert a pathogenic effect has been adequately defined. For instance, chrysotile asbestos fiber is significantly less biopersistent than amphibole asbestos, yet the fiber is clearly carcinogenic and fibrogenic in humans. In view of the many different mechanisms by which fibers might influence the carcinogenic process, it is difficult to determine the degree of biopersistence necessary for fiber carcinogenicity. In addition, available models of fiber solubility or durability in physiological systems, as well as fiber biopersistence in the lung, remain to be validated. Nevertheless, it is generally believed that fibers capable of biopersistence in the lung are of greater concern.
Other fiber characteristics such as surface area, chemistry, and chemical leaching are also likely to play a role in fiber-induced toxicity and carcinogenicity, although these are much less well understood. For example, acid-leached chrysotile fibers are less carcinogenic than native fibers (16) .
Definition ofFibers ofConcern
A major issue for the U.S. EPA is to define the category of fiber of concern. As discussed above, it is recognized that there are a number of fiber properties e.g., fiber size, chemical composition, biopersistence, and surface chemistry that are likely to exert an influence on the pulmonary toxicity and carcinogenicity of inhaled fibers. However, it is the presence of a long thin fibrous shape that appears to be the most important determinant of fiberinduced pathogenicity. Still, it is not known whether there is any single cutoff of fiber length or diameter that implies human safety. Moreover, the conventional definition of a fiber used for industrial hygiene purposes continues to be a practical index for risk assessment. Consequently, fibrous particles of respirable sizes are considered potentially hazardous unless there are available data to demonstrate otherwise.
For regulatory purposes, the U.S. EPA defines fiber as a particle of length > 5 pm with an aspect ratio (ratio of fiber length to fiber diameter) of at least 3:1 (4). This definition has been widely adopted by other organizations (17, 18) . Fibers with aerodynamic diameters of 10 to 12 pm or less, or actual fiber diameter of about 3.0 to 3.5 pm or less, are generally considered respirable for humans (19 On the other hand, lack of tumorigenic responses in an inhalation study does not necessarily mean that the fiber is nonhazardous to humans, because of species differences in the respirability and susceptibility between humans and rodents as discussed above. Such a finding, however, would strongly indicate that the fiber does not exhibit carcinogenic potential in humans if it was demonstrated that the target tissues (i.e., the lung) were exposed to sufficient quantities of critical-size fibers compared with a positive control (e.g., asbestos). Evidence for the absence of carcinogenic potential of the fiber in humans must be corroborated by consistent lack of biological and toxicological effects from other studies.
Studies using instillation or injection methods of administration are of considerable value for the evaluation of the potential human hazard of fibers. Positive results in instillation or injection studies would suggest a potential hazard to humans, but further investigation would be needed for a firm evaluation ofthe inhalation hazard for humans. However, a negative result in such studies would suggest that the fiber probably is of low human hazard potential and the need for additional inhalation testing would be mitigated. An exception to this would be for fibers that have the ability to agglomerate (certain organic fibers such as p-aramid) and tend to reduce the actual number of single fibers at target tissues. Dose-Response w rapolaton To more accurately predict and characterize human health risks from inhaled fibers, it is necessary to understand the mechanistic linkage between fiber exposure and biologically effective dose and between the biologically effective dose and response. Currently, validated biologically based models and mathematical models describing fiber exposure/dose-response relationships for fiber-induced toxicity and carcinogenicity in quantitative terms are not yet available. There is still a lack of information on the disposition of inhaled fibers both in laboratory animals and humans. Moreover, the knowledge of how fibers cause biological and pathological effects is still incomplete, and the question of how long a fiber has to persist in the target tissue to induce a biologic and pathologic response has yet to be fully investigated. Given the incomplete knowledge of fiber toxicology, the U.S. EPA often uses fiber exposure concentration as a surrogate for dose for risk assessment purposes.
There A regulatory decision is subsequently made either to drop the case from further consideration or take control action to protect against that risk. If it is determined that the fiber is of concern but there are insufficient data to assess the potential health effects of the fiber, control action may be imposed until additional information is obtained. As more information becomes available, the risk assessment is updated and risk management action is adjusted if deemed necessary. Screeninglevel testing may be imposed on a new fiber of low health concern if it is to be produced in large quantities and widely used in commercial products, which could result in substantial human exposure. Testing requirements are considered necessary to ensure that the new fiber does not pose significant risk to exposed humans. For fibers determined to be potentially hazardous, the agency may issue a significant new use rule (SNUR) to prevent the fibers from reentering commerce without U.S. EPA notification.
Hazard Idenfication
Key factors that are generally considered in predicting the health hazard potential of inhaled fibers are: a) the ability of the fiber to generate airborne respirable partides; b) the fiber size distribution of the airborne fibers; c) the morphologic and chemical characteristics of the fiber; d) the in vitro solubiity of the fiber; e) the biopersistence of the fiber in the lung; f) the ability of the fiber to cause cytoxicity, cell proliferation, chromosomal damage, and other biological endpoints in in vitro and in vivo assays; g) the ability of the fiber to cause pathological changes in short term or lifetime studies in laboratory animals by inhalation, IT, and/or ip injection; and h) the toxicity and carcinogenicity profiles of chemically and structurally related fibrous particles.
In the absence of any toxicologic information, a new fibrous material is presumed to pose a fibrogenic hazard if it is respirable. If the new fiber also contains a significant proportion of particles with a long, thin, fibrous shape (fiber diameter < 1 pm and fiber length 2 10 pm), it is considered potentially fibrogenic and carcinogenic. This science policy position is justified, as fiber dimension is an important determinant of fiber toxicity and carcinogenicity. Health concerns about potential carcinogenic and fibrogenic effects of a fiber increase if available information indicates that it is relatively insoluble in physiological systems and biopersists in the lung. The concern is heightened if chemically and structurally related fibrous substances are known to cause in vitro and in vivo toxicity in shortterm studies and/or carcinogenicity in long-term studies.
A fiber is not considered a significant hazard to human health if available information indicates that the fiber is nonrespirable or has a low degree of respirability. A respirable fiber may be of low health concern if the fiber is relatively short, does not biopersist in the lung, is relatively soluble, exhibits low biological and toxicologic effects in in vitro and in vivo short-term studies, and/or demonstrates a lack of fibrogenic and carcinogenic effect in longterm animal studies. Some short fibers may be fibrogenic at high exposure levels but may not be carcinogenic. On the other hand, a carcinogenic fiber is also likely to be fibrogenic.
The minimum data set required by the agency for a screening-level determination of potential health hazards of a new fiber should include a complete physical and chemical characterization of the fiber and the results from a well-designed and well conducted 90-day subchronic inhalation study in the rat. Other toxicologic information such as in vitro solubility, in vitro cellular assays (e.g., cytotoxicity, genotoxicity, cell proliferation, or generation of ROS), and lifetime IT or ip carcinogenicity studies, are considered highly relevant and desirable in the evaluation of the potential hazard of the fiber. However, at the present time, these studies are not part of the regulatory testing requirement for new fibers. The U.S. EPA is in the process of developing fiber toxicity and carcinogenicity testing guidelines for new and existing fibers (24 
Exposure Assessment
The first step in exposure assessment is the evaluation of the life cycle of the fiber (how the fiber is manufactured, processed, used, removed, and disposed of) and the identification of any points in the product life cycle that may result in human exposure by inhalation in the occupational setting, as an end user, or from environmental releases. This is followed by the estimation of the population, frequency, and magnitude of exposure for each potential exposure scenario, and an evaluation of any alterations in the physical and chemical characteristics of the fiber throughout its life cycle. This is important because the physicochemical properties of the fiber are major determinants of toxicity and carcinogenicity.
A major source of uncertainty in the assessment of anticipated human exposure to new fibers is the absence of monitoring data on fiber exposure in the workplace, during use, and from environmental release. As a result, compliance with the permissible exposure limit for respirable nuisance dust (5 (26) .
To date, the agency has taken testing action on only one class of fibers. The agency has concluded that RCF is likely to be carcinogenic and fibrogenic, but exposure data are inadequate to determine if RCF poses an unreasonable risk to workers (27) . Consequently, the U.S. EPA and the manufacturers of RCF developed an exposure monitoring program pursuant to an enforceable consent order to obtain additional worker data (28) . The agency is presently developing guidelines for chronic toxicity and carcinogenicity testing for fibrous particles (24) . The 
